Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)

15 de maio de 2017 atualizado por: Merck Sharp & Dohme LLC

A Pharmacokinetic Study of PEG-Intron, Administered Weekly in Subjects With High-Risk Melanoma

The purpose of this study is to establish the pharmacokinetics of PEG-Intron, administered at a dose of 6 μg/kg/week for 8 weeks (induction treatment), followed by a dose of 3 μg/kg/week for up to 252 weeks (maintenance treatment), in patients with high risk melanoma.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

32

Estágio

  • Fase 1

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Subjects at least 18 years of age, of either sex, and of any race.
  • Cytologically or histologically-confirmed melanoma, arising from a cutaneous or unknown site of origin, at Stages IIB, IIC, IIIA, IIIB, IIIC according to the American Joint Committee on Cancer (AJCC) 2001 guidelines.
  • Adequate hepatic, renal and bone marrow function within 4 weeks prior to initiation of study treatment.
  • Subjects presenting with synchronous primary and regional melanoma must have had adequate surgical margins surrounding the primary lesion.
  • Full lymphadenectomy must be performed within 90 days prior to initiation of study treatment.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Give informed consent according to International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) and national/local policy.
  • Be able to adhere to dose and visit schedules.
  • Female subjects of childbearing potential must be using a medically accepted method of birth control prior to Screening and agree to continue its use during the study or be surgically sterilized.
  • Female subjects of childbearing potential must have a negative serum pregnancy test at Screening.

Exclusion Criteria:

  • Female subjects who are pregnant, intend to become pregnant, or are breastfeeding.
  • Previous treatment with interferon alpha, chemotherapy or immunotherapy for melanoma.
  • Ocular melanoma, or melanoma of the mucous membranes.
  • Evidence of distant or non-regional lymph node metastases.
  • In-transit melanoma, even if the lesion has been resected.
  • Disease that cannot be completely surgically resected.
  • Lack of recovery from recent surgery.
  • Prior malignancy within the past 5 years, except surgically cured squamous cell carcinoma of the skin, successfully resected early stage cutaneous melanoma, or cervical carcinoma in situ.
  • Severe cardiovascular disease.
  • Thyroid dysfunction not responsive to therapy.
  • Uncontrolled diabetes mellitus (in the opinion of the investigator).
  • Active autoimmune disease.
  • Active and/or uncontrolled infection.
  • History of seropositivity for human immunodeficiency virus (HIV).
  • Pre-existing psychiatric condition.
  • Clinical diagnosis of substance abuse of one or more of the following drugs within the following timeframes (excluding time spent in detoxification, hospitalization or incarceration):

    • Alcohol, intravenous drug use, inhalational, psychotropics, narcotics, cocaine, prescription or over-the-counter drugs: within 1 year of the Screening visit.
    • Methadone, buprenorphine hydrochloride (HCl), and/or butorphanol tartrate: within 1 year of Screening visit, unless subject has drug screen negative for other (non-narcotic) drugs documented in the past year and repeated negative within 2 months of Screening visit.
    • Multi-drug abuse (2 or more substances in 16a and 16b): within 3 years of Screening visit.
    • Marijuana:

      • If historic use is deemed excessive by the principal investigator (or medically qualified individual), or is interfering with the subject's life, then the subject is not eligible and should not be screened.
      • If marijuana use is not deemed excessive by principal investigator and does not interfere with life, subject must discontinue any current use of marijuana prior to entry into study.
  • Medical condition requiring chronic systemic corticosteroids.
  • Known allergy to the drug substance or any of the excipients in the PEG-Intron formulation.
  • Any situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
  • Use of any investigational drugs within 30 days of study entry.
  • Participation in other clinical studies of investigational treatments.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: PEG-Intron

6 ug/kg/week, SC (first 8 weeks)

3 ug/kg/week, SC (252 weeks [weeks 9-260], maintenance)

Outros nomes:
  • SCH 054031
  • peginterferon alfa-2b

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Area Under the Curve (AUC) of PEG-Intron at 12 Weeks
Prazo: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
AUC was defined as the actual body exposure to drug after administration of a dose of the drug.
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Maximum Serum Concentration (Cmax) of PEG-Intron at 12 Weeks
Prazo: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Cmax was defined as observed maximum plasma concentration.
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Average Concentration Within the Dosing Interval (Cavg) of PEG-Intron at 12 Weeks
Prazo: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Cavg was defined as average plasma concentration.
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Minimum Serum Concentration (Cmin) of PEG-Intron at 12 Weeks
Prazo: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Cmin was defined as observed minimum plasma concentration.
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Observed Time to Achieve Cmax (Tmax) of PEG-Intron at 12 Weeks
Prazo: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Tmax was defined as time of maximum plasma concentration.
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Apparent Clearance(CL/F) of PEG-Intron at 12 Weeks
Prazo: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
CL/F was defined apparent clearance - the volume of plasma in the vascular compartment cleared of drug per unit of time and per kilogram of body weight by the processes of metabolism and excretion.
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number of Participants Who Experienced an Adverse Event (AE)
Prazo: Entire study duration (up to 5 years)
An adverse event (AE) was defined as any untoward medical occurrence or unfavorable and unintended sign in a subject administered a pharmaceutical product, biologic (at any dose), or medical device, whether or not considered related to the use of that product.
Entire study duration (up to 5 years)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

20 de fevereiro de 2007

Conclusão Primária (Real)

27 de maio de 2008

Conclusão do estudo (Real)

11 de julho de 2012

Datas de inscrição no estudo

Enviado pela primeira vez

5 de abril de 2007

Enviado pela primeira vez que atendeu aos critérios de CQ

5 de abril de 2007

Primeira postagem (Estimativa)

6 de abril de 2007

Atualizações de registro de estudo

Última Atualização Postada (Real)

7 de junho de 2017

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de maio de 2017

Última verificação

1 de maio de 2017

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever